Abbott sees accelerating sales growth in 2H14 The company expects to achieve double digit EPS growth this year despite reporting an unfavorable Exchange impact of 3% on sales in Q1. The company said it is "right on track" with the sales progression it expected in January with sales growth before exchange essentially the same as its planned forecast. Abbott expects continued momentum in Established Pharmaceuticals, particularly in Brazil and India. It sees continued in improvement in growth rate with emerging markets becoming a larger component of the business. Expects double sales growth and operating margin for Nutrition in 2H14. Comments taken from Q1 earnings conference call.